Kenvue Inc. (NYSE:KVUE) Receives Consensus Rating of “Hold” from Brokerages

Kenvue Inc. (NYSE:KVUE) has received a consensus rating of “Hold” from the nineteen analysts that are presently covering the firm, Marketbeat reports. Thirteen research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $20.2333.

Several equities analysts have recently commented on KVUE shares. Bank of America lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, October 8th. Citigroup lowered their price target on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, October 9th. Johnson Rice reiterated a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Edward Jones cut Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Finally, UBS Group decreased their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th.

Hedge Funds Weigh In On Kenvue

Institutional investors have recently bought and sold shares of the stock. Truvestments Capital LLC bought a new stake in Kenvue during the 1st quarter valued at about $37,000. Cornerstone Planning Group LLC increased its holdings in shares of Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares in the last quarter. NBT Bank N A NY raised its stake in shares of Kenvue by 180.3% in the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares during the last quarter. Salomon & Ludwin LLC bought a new position in shares of Kenvue during the third quarter valued at $25,000. Finally, Trust Co. of Vermont boosted its position in shares of Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $16.98 on Wednesday. The stock has a market cap of $32.52 billion, a PE ratio of 22.64 and a beta of 0.60. The company’s fifty day moving average is $16.11 and its 200 day moving average is $19.19. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue has a 52 week low of $14.02 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. During the same period in the previous year, the firm earned $0.28 EPS. The business’s quarterly revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts anticipate that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.9%. The ex-dividend date of this dividend was Wednesday, November 12th. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.